200 related articles for article (PubMed ID: 33106353)
1. Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.
Bayo J; Fiore EJ; Dominguez LM; Cantero MJ; Ciarlantini MS; Malvicini M; Atorrasagasti C; Garcia MG; Rossi M; Cavasotto C; Martinez E; Comin J; Mazzolini GD
Gut; 2021 Jul; 70(7):1362-1374. PubMed ID: 33106353
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline causes loss of cell viability mediated by mitochondrial OXPHOS and RAC1 in hepatocellular carcinoma cells.
Koch DT; Yu H; Beirith I; Schirren M; Drefs M; Liu Y; Knoblauch M; Koliogiannis D; Sheng W; De Toni EN; Bazhin AV; Renz BW; Guba MO; Werner J; Ilmer M
J Transl Med; 2023 Dec; 21(1):876. PubMed ID: 38041179
[TBL] [Abstract][Full Text] [Related]
4. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
5. AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro.
Böttcher K; Longato L; Marrone G; Mazza G; Ghemtio L; Hall A; Luong TV; Caruso S; Viollet B; Zucman-Rossi J; Pinzani M; Rombouts K
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G543-G556. PubMed ID: 33406006
[TBL] [Abstract][Full Text] [Related]
6. The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Qin CD; Ma DN; Zhang SZ; Zhang N; Ren ZG; Zhu XD; Jia QA; Chai ZT; Wang CH; Sun HC; Tang ZY
Cell Death Dis; 2018 May; 9(5):486. PubMed ID: 29706627
[TBL] [Abstract][Full Text] [Related]
7. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma.
Sauzeau V; Beignet J; Vergoten G; Bailly C
Pharmacol Res; 2022 May; 179():106220. PubMed ID: 35405309
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of invasion and metastasis of hepatocellular carcinoma cells via targeting RhoC in vitro and in vivo.
Wang W; Wu F; Fang F; Tao Y; Yang L
Clin Cancer Res; 2008 Nov; 14(21):6804-12. PubMed ID: 18980974
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
10. T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1.
Ji X; Chen X; Zhang B; Xie M; Zhang T; Luo X; Liu D; Feng Y; Wang Y; Sun M; Li C; Huang W; Xia L
Oncogene; 2022 Apr; 41(15):2225-2238. PubMed ID: 35217793
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.
Rosenblatt AE; Garcia MI; Lyons L; Xie Y; Maiorino C; Désiré L; Slingerland J; Burnstein KL
Endocr Relat Cancer; 2011 Apr; 18(2):207-19. PubMed ID: 21118977
[TBL] [Abstract][Full Text] [Related]
12. The NKD1/Rac1 feedback loop regulates the invasion and migration ability of hepatocarcinoma cells.
Li J; Zhang S; Hu Q; Zhang K; Jin J; Zheng X; Yin Z; Wang X
Sci Rep; 2016 May; 6():26971. PubMed ID: 27231134
[TBL] [Abstract][Full Text] [Related]
13. Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.
Cardama GA; Comin MJ; Hornos L; Gonzalez N; Defelipe L; Turjanski AG; Alonso DF; Gomez DE; Menna PL
Anticancer Agents Med Chem; 2014; 14(6):840-51. PubMed ID: 24066799
[TBL] [Abstract][Full Text] [Related]
14. The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells.
Bu Y; Jia QA; Ren ZG; Xue TC; Zhang QB; Zhang KZ; Zhang QB; You Y; Tian H; Qin LX; Tang ZY
Oncotarget; 2015 Nov; 6(37):40068-80. PubMed ID: 26517671
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.
Fuchs BC; Hoshida Y; Fujii T; Wei L; Yamada S; Lauwers GY; McGinn CM; DePeralta DK; Chen X; Kuroda T; Lanuti M; Schmitt AD; Gupta S; Crenshaw A; Onofrio R; Taylor B; Winckler W; Bardeesy N; Caravan P; Golub TR; Tanabe KK
Hepatology; 2014 Apr; 59(4):1577-90. PubMed ID: 24677197
[TBL] [Abstract][Full Text] [Related]
16. LncRNA PCAT6 predicts poor prognosis in hepatocellular carcinoma and promotes proliferation through the regulation of cell cycle arrest and apoptosis.
Luo Y; Lin J; Zhang Y; Dai G; Li A; Liu X
Cell Biochem Funct; 2020 Oct; 38(7):895-904. PubMed ID: 32064636
[TBL] [Abstract][Full Text] [Related]
17. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes.
Jang JW; Song Y; Kim KM; Kim JS; Choi EK; Kim J; Seo H
BMC Cancer; 2016 Oct; 16(1):810. PubMed ID: 27756242
[TBL] [Abstract][Full Text] [Related]
19. A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination.
Ahronian LG; Zhu LJ; Chen YW; Chu HC; Klimstra DS; Lewis BC
Oncogene; 2016 Sep; 35(35):4653-62. PubMed ID: 26876204
[TBL] [Abstract][Full Text] [Related]
20. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma.
Chen J; Xia H; Zhang X; Karthik S; Pratap SV; Ooi LL; Hong W; Hui KM
J Hepatol; 2015 Jun; 62(6):1287-95. PubMed ID: 25617497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
